Differential abundance of CK1a provides selectivity for pharmacological CK1a activators to target WNT-dependent tumors

Bin Li, Darren Orton, Leif R. Neitzel, Luisana Astudillo, Chen Shen, Jun Long, Xi Chen, Kellye C. Kirkbride, Thomas Doundoulakis, Marcy L. Guerra, Julia Zaias, Dennis Liang Fei, Jezabel Rodriguez-Blanco, Curtis Thorne, Zhiqiang Wang, Ke Jin, Dao Nguyen, Laurence Sands, Floriano Marchetti, Maria T AbreuMelanie H. Cobb, Anthony J Capobianco, Ethan Lee, David J. Robbin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Constitutive WNT activity drives the growth of various human tumors, including nearly all colorectal cancers (CRCs). Despite this prominence in cancer, no WNT inhibitor is currently approved for use in the clinic largely due to the small number of druggable signaling components in the WNT pathway and the substantial toxicity to normal gastrointestinal tissue. We have shown that pyrvinium, which activates casein kinase 1a (CK1α), is a potent inhibitor of WNT signaling. However, its poor bioavailability limited the ability to test this first-in-class WNT inhibitor in vivo. We characterized a novel small-molecule CK1α activator called SSTC3, which has better pharmacokinetic properties than pyrvinium, and found that it inhibited the growth of CRC xenografts in mice. SSTC3 also attenuated the growth of a patient-derived metastatic CRC xenograft, for which few therapies exist. SSTC3 exhibited minimal gastrointestinal toxicity compared to other classes of WNT inhibitors. Consistent with this observation, we showed that the abundance of the SSTC3 target, CK1α, was decreased in WNT-driven tumors relative to normal gastrointestinal tissue, and knocking down CK1α increased cellular sensitivity to SSTC3. Thus, we propose that distinct CK1α abundance provides an enhanced therapeutic index for pharmacological CK1a activators to target WNT-driven tumors.

Original languageEnglish (US)
Article numberaak9916
JournalScience Signaling
Volume10
Issue number485
DOIs
StatePublished - Jun 27 2017

Fingerprint

Casein Kinases
Tumors
Pharmacology
Colorectal Neoplasms
Neoplasms
Heterografts
Toxicity
Growth
Tissue
Pharmacokinetics
Biological Availability
Molecules
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Li, B., Orton, D., Neitzel, L. R., Astudillo, L., Shen, C., Long, J., ... Robbin, D. J. (2017). Differential abundance of CK1a provides selectivity for pharmacological CK1a activators to target WNT-dependent tumors. Science Signaling, 10(485), [aak9916]. https://doi.org/10.1126/scisignal.aak9916

Differential abundance of CK1a provides selectivity for pharmacological CK1a activators to target WNT-dependent tumors. / Li, Bin; Orton, Darren; Neitzel, Leif R.; Astudillo, Luisana; Shen, Chen; Long, Jun; Chen, Xi; Kirkbride, Kellye C.; Doundoulakis, Thomas; Guerra, Marcy L.; Zaias, Julia; Fei, Dennis Liang; Rodriguez-Blanco, Jezabel; Thorne, Curtis; Wang, Zhiqiang; Jin, Ke; Nguyen, Dao; Sands, Laurence; Marchetti, Floriano; Abreu, Maria T; Cobb, Melanie H.; Capobianco, Anthony J; Lee, Ethan; Robbin, David J.

In: Science Signaling, Vol. 10, No. 485, aak9916, 27.06.2017.

Research output: Contribution to journalArticle

Li, B, Orton, D, Neitzel, LR, Astudillo, L, Shen, C, Long, J, Chen, X, Kirkbride, KC, Doundoulakis, T, Guerra, ML, Zaias, J, Fei, DL, Rodriguez-Blanco, J, Thorne, C, Wang, Z, Jin, K, Nguyen, D, Sands, L, Marchetti, F, Abreu, MT, Cobb, MH, Capobianco, AJ, Lee, E & Robbin, DJ 2017, 'Differential abundance of CK1a provides selectivity for pharmacological CK1a activators to target WNT-dependent tumors', Science Signaling, vol. 10, no. 485, aak9916. https://doi.org/10.1126/scisignal.aak9916
Li, Bin ; Orton, Darren ; Neitzel, Leif R. ; Astudillo, Luisana ; Shen, Chen ; Long, Jun ; Chen, Xi ; Kirkbride, Kellye C. ; Doundoulakis, Thomas ; Guerra, Marcy L. ; Zaias, Julia ; Fei, Dennis Liang ; Rodriguez-Blanco, Jezabel ; Thorne, Curtis ; Wang, Zhiqiang ; Jin, Ke ; Nguyen, Dao ; Sands, Laurence ; Marchetti, Floriano ; Abreu, Maria T ; Cobb, Melanie H. ; Capobianco, Anthony J ; Lee, Ethan ; Robbin, David J. / Differential abundance of CK1a provides selectivity for pharmacological CK1a activators to target WNT-dependent tumors. In: Science Signaling. 2017 ; Vol. 10, No. 485.
@article{99dabcad7e304ecab19b972680156aac,
title = "Differential abundance of CK1a provides selectivity for pharmacological CK1a activators to target WNT-dependent tumors",
abstract = "Constitutive WNT activity drives the growth of various human tumors, including nearly all colorectal cancers (CRCs). Despite this prominence in cancer, no WNT inhibitor is currently approved for use in the clinic largely due to the small number of druggable signaling components in the WNT pathway and the substantial toxicity to normal gastrointestinal tissue. We have shown that pyrvinium, which activates casein kinase 1a (CK1α), is a potent inhibitor of WNT signaling. However, its poor bioavailability limited the ability to test this first-in-class WNT inhibitor in vivo. We characterized a novel small-molecule CK1α activator called SSTC3, which has better pharmacokinetic properties than pyrvinium, and found that it inhibited the growth of CRC xenografts in mice. SSTC3 also attenuated the growth of a patient-derived metastatic CRC xenograft, for which few therapies exist. SSTC3 exhibited minimal gastrointestinal toxicity compared to other classes of WNT inhibitors. Consistent with this observation, we showed that the abundance of the SSTC3 target, CK1α, was decreased in WNT-driven tumors relative to normal gastrointestinal tissue, and knocking down CK1α increased cellular sensitivity to SSTC3. Thus, we propose that distinct CK1α abundance provides an enhanced therapeutic index for pharmacological CK1a activators to target WNT-driven tumors.",
author = "Bin Li and Darren Orton and Neitzel, {Leif R.} and Luisana Astudillo and Chen Shen and Jun Long and Xi Chen and Kirkbride, {Kellye C.} and Thomas Doundoulakis and Guerra, {Marcy L.} and Julia Zaias and Fei, {Dennis Liang} and Jezabel Rodriguez-Blanco and Curtis Thorne and Zhiqiang Wang and Ke Jin and Dao Nguyen and Laurence Sands and Floriano Marchetti and Abreu, {Maria T} and Cobb, {Melanie H.} and Capobianco, {Anthony J} and Ethan Lee and Robbin, {David J.}",
year = "2017",
month = "6",
day = "27",
doi = "10.1126/scisignal.aak9916",
language = "English (US)",
volume = "10",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "485",

}

TY - JOUR

T1 - Differential abundance of CK1a provides selectivity for pharmacological CK1a activators to target WNT-dependent tumors

AU - Li, Bin

AU - Orton, Darren

AU - Neitzel, Leif R.

AU - Astudillo, Luisana

AU - Shen, Chen

AU - Long, Jun

AU - Chen, Xi

AU - Kirkbride, Kellye C.

AU - Doundoulakis, Thomas

AU - Guerra, Marcy L.

AU - Zaias, Julia

AU - Fei, Dennis Liang

AU - Rodriguez-Blanco, Jezabel

AU - Thorne, Curtis

AU - Wang, Zhiqiang

AU - Jin, Ke

AU - Nguyen, Dao

AU - Sands, Laurence

AU - Marchetti, Floriano

AU - Abreu, Maria T

AU - Cobb, Melanie H.

AU - Capobianco, Anthony J

AU - Lee, Ethan

AU - Robbin, David J.

PY - 2017/6/27

Y1 - 2017/6/27

N2 - Constitutive WNT activity drives the growth of various human tumors, including nearly all colorectal cancers (CRCs). Despite this prominence in cancer, no WNT inhibitor is currently approved for use in the clinic largely due to the small number of druggable signaling components in the WNT pathway and the substantial toxicity to normal gastrointestinal tissue. We have shown that pyrvinium, which activates casein kinase 1a (CK1α), is a potent inhibitor of WNT signaling. However, its poor bioavailability limited the ability to test this first-in-class WNT inhibitor in vivo. We characterized a novel small-molecule CK1α activator called SSTC3, which has better pharmacokinetic properties than pyrvinium, and found that it inhibited the growth of CRC xenografts in mice. SSTC3 also attenuated the growth of a patient-derived metastatic CRC xenograft, for which few therapies exist. SSTC3 exhibited minimal gastrointestinal toxicity compared to other classes of WNT inhibitors. Consistent with this observation, we showed that the abundance of the SSTC3 target, CK1α, was decreased in WNT-driven tumors relative to normal gastrointestinal tissue, and knocking down CK1α increased cellular sensitivity to SSTC3. Thus, we propose that distinct CK1α abundance provides an enhanced therapeutic index for pharmacological CK1a activators to target WNT-driven tumors.

AB - Constitutive WNT activity drives the growth of various human tumors, including nearly all colorectal cancers (CRCs). Despite this prominence in cancer, no WNT inhibitor is currently approved for use in the clinic largely due to the small number of druggable signaling components in the WNT pathway and the substantial toxicity to normal gastrointestinal tissue. We have shown that pyrvinium, which activates casein kinase 1a (CK1α), is a potent inhibitor of WNT signaling. However, its poor bioavailability limited the ability to test this first-in-class WNT inhibitor in vivo. We characterized a novel small-molecule CK1α activator called SSTC3, which has better pharmacokinetic properties than pyrvinium, and found that it inhibited the growth of CRC xenografts in mice. SSTC3 also attenuated the growth of a patient-derived metastatic CRC xenograft, for which few therapies exist. SSTC3 exhibited minimal gastrointestinal toxicity compared to other classes of WNT inhibitors. Consistent with this observation, we showed that the abundance of the SSTC3 target, CK1α, was decreased in WNT-driven tumors relative to normal gastrointestinal tissue, and knocking down CK1α increased cellular sensitivity to SSTC3. Thus, we propose that distinct CK1α abundance provides an enhanced therapeutic index for pharmacological CK1a activators to target WNT-driven tumors.

UR - http://www.scopus.com/inward/record.url?scp=85021626706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021626706&partnerID=8YFLogxK

U2 - 10.1126/scisignal.aak9916

DO - 10.1126/scisignal.aak9916

M3 - Article

C2 - 28655862

AN - SCOPUS:85021626706

VL - 10

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 485

M1 - aak9916

ER -